The China Valve (Hangzhou) 2022, sponsored by the Second Affiliated Hospital Zhejiang University School of Medicine, supported by CSI (Catheter Interventions in Congenital, Structural and Valvular Heart diseases) will be held from April 25th to May 1st in both online and offline forms to present a more innovative, advanced, common-touched academic conference on heart valvular diseases.

　　With the support of colleagues around the world, China Valve (Hangzhou) has grown into a well-recognized brand of academic conference in the field of structural heart disease domestically and internationally. China Valve (Hangzhou) 2022 would display cutting-edge progress in the field of valvular heart disease intervention, with an open mind, inclusive ethos and multiple perspectives.

　　China Valve (Hangzhou) 2022 will continue to conduct joint forums and symposiums with TVT (The Structural Heart Summit), and start dialogues on the frontiers of disciplines through platforms such as JACC: Asia Focus Seminar on Innovation. The Global Live Demo and National TAVR Live Demo will present the latest clinical devices of transcatheter mitral valve repair/replacement (TMVr/R), transcatheter tricuspid valve repair/replacement (TTVr/R), transcatheter pulmonary valve replacement (TPVR) in addition to deep exihibition of transcatheter aortic valve replacement (TAVR) in past years by live and recorded cases. The conference set up Workshops and Basic Training Courses, covering special sessions such as anatomy, CT and Proglide forums, as well as echocardiography, anesthesia and basic research forums, to provide systematic training for centers planning to carry out valvular interventions, to improve techniques for centers that have already started valvular interventions, and to provide a cooperation platform for experienced valve intervention centers.

　　We are looking forward to meeting you in Hangzhou, enjoying the beautiful spring scenery of the West Lake and propelling technological innovation!